Journal of Emergencies, Trauma, and Shock
Home About us Editors Ahead of Print Current Issue Archives Search Instructions Subscribe Advertise Login 
Users online:189   Print this pageEmail this pageSmall font sizeDefault font sizeIncrease font size   


 
 Table of Contents    
EDITORIAL  
Year : 2021  |  Volume : 14  |  Issue : 3  |  Page : 121-122
What's new in emergencies, trauma, and shock: Head Injury in anticoagulated patients – an enigma


Department of Medicine, IGMC, Shimla, Himachal Pradesh, India

Click here for correspondence address and email

Date of Submission17-Sep-2021
Date of Acceptance21-Sep-2021
Date of Web Publication30-Sep-2021
 

How to cite this article:
Chauhan V. What's new in emergencies, trauma, and shock: Head Injury in anticoagulated patients – an enigma. J Emerg Trauma Shock 2021;14:121-2

How to cite this URL:
Chauhan V. What's new in emergencies, trauma, and shock: Head Injury in anticoagulated patients – an enigma. J Emerg Trauma Shock [serial online] 2021 [cited 2021 Nov 27];14:121-2. Available from: https://www.onlinejets.org/text.asp?2021/14/3/121/327086




The current issue of the Journal of Emergencies, Trauma, and Shock features an article on intracranial hemorrhage (ICH) in head injury patients on warfarin or direct oral anticoagulants (DOAC). In this article, the patients on warfarin had a higher rate of ICH compared to DOAC, however, the rate of delayed ICH was comparable between the two.[1]

There is sparse and conflicting evidence directing the outcomes and management of head injury in patients anticoagulated with DOAC.[2] DOAC have become the new standard anticoagulants replacing the Vitamin K antagonists (VKA) in clinical practice worldwide. Research on the outcomes of such patients of traumatic brain injury (TBI) becomes important to guide the management practices. The guidelines recommend immediate computed tomography (CT) of the brain in suspected or known TBI in those having potential or known intake of anticoagulants.[3] The risk of ICH appears to be higher with VKA as compared to the antiplatelets and DOAC.[3] The guidelines are based on the systematic reviews of the available literature, but we need to take the results of these systematic reviews with a pinch of salt because the studies they included were very heterogeneous in the nature of their study designs and inclusion and exclusion criteria.[2]

Based on the evidence available, a repeat CT is needed only in those patients having documented ICH in the initial CT or those with normal initial CT who deteriorate during observation or after discharge or those who cannot be examined neurologically due to intubation, sedation, or dementia.[2],[3],[4]

Anticoagulated patients with minor head injury are mostly elders who suffer a ground-level fall leading to a minor head injury.[2] They make the bulk of emergency department (ED) referrals for assessment and observation. Physicians in ED should be clear in their approach to such patients. Most systematic reviews on these patients suggest that if initial CT head does not show ICH, the patients with minor head injury do not need a routine repeat CT to rule out delayed ICH irrespective of whether they were taking warfarin, DOAC, or antiplatelets.[2],[4],[5],[6] Other factors such as age and brain atrophy may be more important factors for delayed ICH than the choice of anticoagulant used.[4]

ED physicians may encounter patients with unknown history of medication intake. In such patients, the platelet function tests are recommended to confirm or rule out platelet inhibitor intake.[3] Thrombin time or dilute thrombin time is recommended to rule out dabigatran intake and anti-activated factor-X activity to rule out apixaban intake.[3]

In patients with ICH after TBI, reversal of VKA is recommended using four-factor prothrombin complex concentrate (PCC) and role of Vitamin K is adjunctive.[3] PCC is also recommended in TBI if laboratory testing of anti-Xa activity is unavailable for patients on apixaban, edoxaban, or rivaroxaban.[3] Idarucizumab is recommended in the absence of laboratory testing of thrombin time to reverse the effect of dabigatran. But wherever available, laboratory testing should guide the use of reversal agents for DOAC. Low-molecular-weight heparin should be started 24 h after injury in a clinically and radiologically stable TBI in those needing anticoagulation for underlying illnesses.[3]

The definition of minor head injury is not uniform among the published studies. Glasgow Coma Scale (GCS) of 13–15, GCS of 14–15, and GCS of 15 with loss of consciousness, amnesia, or deterioration are some of the criteria used to define minor head injury by various investigators. Similarly, the inclusion criteria used were variable, e.g., patient age >55, only the patients brought by emergency medical services, patients having ground-level falls only, or patients having any kind of head injury.[2] The outcome measures were, however, comparable among most studies that included death, disability, neurosurgery, or readmission within 1 month.[2]

It is also prudent to study the limitations of the available systematic reviews on this topic. Any further research on the anticoagulated patients with head injury should include uniform definitions inclusion and follow-up criteria, and outcome measures so that they are all inclusive and generalizable to the wide spectrum of head injuries. Also, most published research is retrospective chart reviews which limits the level of evidence generated on this topic. Therefore, future studies need to be multicentric and prospective in design to be more meaningful and informative.

Comparison between VKA and DOAC has been the central theme of most recent studies. Since DOAC have replaced VKA in clinical practice, we need newer research ideas focused on DOAC.

Reversal of anticoagulation and antiplatelets also needs further research. There is insufficient evidence on the role of desmopressin, platelet transfusion, or tranexamic acid in reversing the effect of antiplatelet drugs.[3]

To conclude, the management of TBI in anticoagulated patients needs multicentric prospectively done research focusing on key areas of management. In the absence of good quality large prospective studies, the available evidence is conflicting in many areas of TBI in anticoagulated patients.



 
   References Top

1.
Hughes PG, Alter SM, Greaves SW, Mazer BA, Solano JJ, Shih RD, et al. Acute and delayed intracranial hemorrhage in head-injured patients on warfarin versus direct oral anticoagulant therapy. J Emerg Trauma Shock 2021;14:123-7.  Back to cited text no. 1
  [Full text]  
2.
Fuller G, Sabir L, Evans R, Bradbury D, Kuczawski M, Mason SM. Risk of significant traumatic brain injury in adults with minor head injury taking direct oral anticoagulants: A cohort study and updated meta-analysis. Emerg Med J 2020;37:666.  Back to cited text no. 2
    
3.
Wiegele M, Schöchl H, Haushofer A, Ortler M, Leitgeb J, Kwasny O, et al. Diagnostic and therapeutic approach in adult patients with traumatic brain injury receiving oral anticoagulant therapy: An Austrian interdisciplinary consensus statement. Crit Care 2019;23:62.  Back to cited text no. 3
    
4.
Huang GS, Dunham CM, Chance EA, Hileman BM. Detecting delayed intracranial hemorrhage with repeat head imaging in trauma patients on antithrombotics with no hemorrhage on the initial image: A retrospective chart review and meta-analysis. Am J Surg 2020;220:55-61.  Back to cited text no. 4
    
5.
Chauny JM, Marquis M, Bernard F, Williamson D, Albert M, Laroche M, et al. Risk of delayed intracranial hemorrhage in anticoagulated patients with mild traumatic brain injury: Systematic review and meta-analysis. J Emerg Med 2016;51:519-28.  Back to cited text no. 5
    
6.
Puzio TJ, Murphy PB, Kregel HR, Ellis RC, Holder T, Wandling MW, et al. Delayed intracranial hemorrhage after blunt head trauma while on direct oral anticoagulant: Systematic review and meta-analysis. J Am Coll Surg 2021;232:1007-16.e5.  Back to cited text no. 6
    

Top
Correspondence Address:
Vivek Chauhan
Department of Medicine, IGMC, Shimla, Himachal Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jets.jets_125_21

Rights and Permissions




 

Top
  
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Email Alert *
    Add to My List *
* Registration required (free)  


    References

 Article Access Statistics
    Viewed436    
    Printed36    
    Emailed0    
    PDF Downloaded12    
    Comments [Add]    

Recommend this journal